Skip to main content
CHNXF logo

ChitogenX Inc. (CHNXF) Stock Price & Analysis

Educational signal · not a buy or sell recommendation · How to read this

$0.00755 $0.00 (0.00%)
Vol: 50.0K| 52-wk range: $0.0011 – $0.00755
Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

ChitogenX Inc. (CHNXF) trades at $0.00755. ChitogenX Inc. is a Canadian orthopaedic and sports medicine biologics company focused on developing soft tissue repair technologies. Their lead product candidates target rotator cuff, meniscus, articular cartilage, osteoarthritis, and tendon injuries. Sector: Healthcare.

Price as of · Last analyzed: Mar 16, 2026
ChitogenX Inc. is a Canadian orthopaedic and sports medicine biologics company focused on developing soft tissue repair technologies. Their lead product candidates target rotator cuff, meniscus, articular cartilage, osteoarthritis, and tendon injuries.

Analyst Coverage for CHNXF: CHNXF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.

No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • RLYB · Rallybio Corporation · 82 /100
  • ICCC · ImmuCell Corporation · 82 /100
  • ORMP · Oramed Pharmaceuticals Inc. · 72 /100

See all scored stocks →

ChitogenX Inc. (CHNXF) Healthcare & Pipeline Overview

CEOPierre Laurin
Employees5
HeadquartersKirkland, CA
IPO Year2020

ChitogenX Inc. is a biotechnology company developing novel therapeutic soft tissue repair technologies for the orthopaedic and sports medicine market. Their pipeline focuses on biopolymer formulations like Ortho-R and Ortho-M, aiming to improve surgical outcomes for common sports-related injuries in Canada.

Data Provenance | Financial Data Quantitative Analysis Analysis: Mar 16, 2026

What Is the Investment Thesis for CHNXF?

AI-written as of Mar 16, 2026 — figures and tone reflect the data available then, not today's score.

ChitogenX presents a speculative investment opportunity within the orthopaedic biologics space. The company's focus on soft tissue repair technologies, particularly its Ortho-R and Ortho-M formulations, addresses a significant market need. Successful clinical trials and regulatory approvals could drive substantial value. However, the company's OTC listing and limited financial data necessitate careful due diligence. Key catalysts include upcoming clinical trial results and potential partnerships. The negative P/E ratio of -0.23 reflects the company's current lack of profitability, typical for early-stage biotech firms. Investors should closely monitor cash burn and potential dilution. The beta of -2.19 suggests the stock is less volatile than the market, but this may be due to low trading volume.

Based on FMP financials and quantitative analysis

CHNXF Key Highlights

AI-written as of Mar 16, 2026 — figures and tone reflect the data available then, not today's score.

Focus on orthopaedic and sports medicine biologics, a growing area within healthcare.

  • Development of Ortho-R for rotator cuff repair, targeting a large market segment.
  • Pipeline includes Ortho-M, Ortho-C, Ortho-V, and Ortho-T, addressing multiple soft tissue injuries.
  • Relatively young company, incorporated in 2015, indicating potential for high growth but also higher risk.
  • Trades on the OTC market, which presents both opportunities and challenges for investors.

Who Are CHNXF's Competitors?

CHNXF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
RLYB Rallybio Corporation $15.26 -0.20% $85.5M 82 5-pillar
ICCC ImmuCell Corporation $11.25 -0.71% $102M 82 5-pillar
ORMP Oramed Pharmaceuticals Inc. $3.89 +0.52% $169M 72 5-pillar
CGEN Compugen Ltd. $1.88 -4.08% $178M 69 5-pillar
PLX Protalix BioTherapeutics, Inc. $3.06 +1.32% $258M 90 5-pillar
FENC Fennec Pharmaceuticals Inc. $13.33 -1.84% $471M 91 5-pillar
INDP Indaptus Therapeutics, Inc. $3.13 -4.86% $481M 60 5-pillar
HELP Cybin Inc. $6.78 -1.60% $541M 60 5-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CHNXF's Key Strengths?

Proprietary biopolymer technology platform.

  • Focus on a growing market segment (orthopaedic biologics).
  • Pipeline of product candidates targeting various soft tissue injuries.
  • Experienced management team with expertise in regenerative medicine.

What Are CHNXF's Weaknesses?

Early-stage company with limited revenue.

  • Reliance on successful clinical trial outcomes.
  • Dependence on external funding.
  • OTC market listing, which can limit liquidity and investor access.

What Are the Key Risks for CHNXF?

Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.

  • Unsuccessful clinical trial outcomes.
  • Regulatory delays or rejections.
  • Competition from established orthopaedic companies.
  • Dependence on external funding.
  • OTC market listing, which can limit liquidity and investor access.

What Are CHNXF's Competitive Advantages?

  • Proprietary biopolymer formulations.
  • Patent protection for its technologies.
  • First-mover advantage in specific market segments.
  • Expertise in orthopaedic biologics.

What Does CHNXF Do?

ChitogenX Inc., formerly known as Ortho Regenerative Technologies Inc., was incorporated in 2015 and is headquartered in Kirkland, Canada. The company operates within the orthopaedic and sports medicine biologics sector, focusing on the research and development of innovative soft tissue repair technologies. ChitogenX aims to enhance the success rate of sports medicine surgeries through its proprietary biopolymer formulations. Their lead product candidates include Ortho-R, a formulation designed for rotator cuff repair, and Ortho-M, a biopolymer intended for meniscus repair. Additionally, the company is developing Ortho-C for articular cartilage repair, Ortho-V for osteoarthritis healing, and ORTHO-T for tendon healing and regeneration. These products are designed to address prevalent sports-related injuries and degenerative conditions, offering potential improvements over existing surgical techniques. The company changed its name to ChitogenX Inc. in September 2022, reflecting its commitment to regenerative medicine in orthopaedics.

What Products and Services Does CHNXF Offer?

  • Develops Ortho-R for rotator cuff repair.
  • Develops Ortho-M for meniscus repair.
  • Develops Ortho-C for articular cartilage repair.
  • Develops Ortho-V for osteoarthritis healing.
  • Develops ORTHO-T for tendon healing and regeneration.
  • Researches and develops novel therapeutic soft tissue repair technologies.
  • Aims to enhance the success rate of sports medicine surgeries.

How Does CHNXF Make Money?

  • Develops and patents biopolymer formulations for orthopaedic applications.
  • Conducts preclinical and clinical trials to demonstrate safety and efficacy.
  • Seeks regulatory approvals for its products in various markets.
  • Commercializes its products through direct sales, partnerships, or licensing agreements.

What Industry Does CHNXF Operate In?

The orthopaedic biologics market is experiencing growth driven by increasing demand for minimally invasive surgical procedures and regenerative medicine solutions. Companies like ChitogenX are positioned to capitalize on this trend by developing innovative therapies for soft tissue repair. The competitive landscape includes established players and emerging biotech firms, all vying for market share in specific segments such as rotator cuff repair, meniscus repair, and osteoarthritis treatment. The market is characterized by a focus on improving surgical outcomes, reducing recovery times, and enhancing the quality of life for patients with musculoskeletal conditions.

Who Are CHNXF's Key Customers?

  • Orthopaedic surgeons.
  • Sports medicine physicians.
  • Hospitals and surgical centers.
  • Patients with soft tissue injuries.
Model self-rating on this text: 71% (not a measure of the evidence) Updated: Mar 16, 2026

Research confidence

Low

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • ● Scoring coverage unknown
  • ● No usable price
  • ● No filing on record
  • ● No analyst coverage
ROE 19%

Key Financial Metrics

Return on equity for ChitogenX Inc. stands at 19.4%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.07 means current liabilities exceed short-term assets, a liquidity point worth watching.

Company Profile

ChitogenX Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Kirkland, CA. The company is led by CEO Pierre Laurin. CHNXF has traded publicly since 2020.

F-Score 2/9

Financial Health

ChitogenX Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

4/8 beats

Earnings Track Record

ChitogenX Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 24.1% above estimates on average.

FY2026 est

Forward Outlook

Wall Street analysts project ChitogenX Inc. revenue of about $0 for fiscal 2026, with EPS near $-0.11.

CHNXF Latest News

No recent news available for CHNXF.

CHNXF Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for CHNXF.

Price Targets

Wall Street price target analysis for CHNXF.

CHNXF MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for CHNXF; grades run from A+ (80-100) to F (below 30).

Leadership: Pierre Laurin

CEO

Pierre Laurin is the CEO of ChitogenX Inc. His background includes extensive experience in the pharmaceutical and biotechnology industries. He has held leadership positions in various companies, focusing on business development, strategic planning, and commercialization of innovative healthcare products. He has a proven track record of driving growth and creating value for shareholders. His expertise spans across multiple therapeutic areas, including orthopaedics and regenerative medicine.

Track Record: Under Pierre Laurin's leadership, ChitogenX has focused on advancing its pipeline of soft tissue repair technologies. He has overseen the company's strategic shift towards regenerative medicine and has been instrumental in securing funding for clinical trials. Key milestones include the development of Ortho-R and Ortho-M, as well as the expansion of the company's intellectual property portfolio.

CHNXF OTC Market Information

The OTC Other tier represents the lowest tier of the OTC market, indicating that ChitogenX may not meet the minimum financial or disclosure requirements for higher tiers like OTCQB or OTCQX. Companies on this tier may have limited financial reporting, potentially increasing investment risk compared to companies listed on major exchanges like the NYSE or NASDAQ, which have stringent listing standards and reporting requirements. This tier often includes companies with limited operating history or those facing financial difficulties.

  • OTC Tier: OTC Other
Liquidity: Trading volume for CHNXF on the OTC market is likely low, which can result in wider bid-ask spreads and make it difficult to buy or sell large quantities of shares without significantly impacting the price. This lack of liquidity can increase the risk of price volatility and make it challenging for investors to exit their positions quickly.
OTC Risk Factors:
  • Limited financial disclosure increases information asymmetry.
  • Low trading volume can lead to price volatility.
  • Higher risk of fraud or manipulation compared to listed exchanges.
  • Limited regulatory oversight.
  • Potential for delisting or trading suspensions.
Due Diligence Checklist:
  • Verify the company's financial statements and SEC filings (if any).
  • Assess the company's management team and their experience.
  • Evaluate the company's business model and competitive landscape.
  • Review the company's intellectual property portfolio.
  • Understand the company's capital structure and potential dilution.
  • Check for any legal or regulatory issues.
  • Consult with a financial advisor.
Legitimacy Signals:
  • Focus on research and development of innovative technologies.
  • Experienced management team with relevant industry expertise.
  • Patent protection for its biopolymer formulations.
  • Collaboration with reputable research institutions.
  • Presence of a clear business plan and strategic vision.

What Investors Ask About ChitogenX Inc. (CHNXF) — Healthcare

What does ChitogenX Inc. do?

ChitogenX Inc. is an orthopaedic and sports medicine biologics company focused on developing and commercializing novel soft tissue repair technologies.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Limited financial data available for CHNXF.
  • OTC market listing increases investment risk.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

Stock Deep Dives